XML 51 R33.htm IDEA: XBRL DOCUMENT
v3.25.0.1

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Revenue from Contract with Customer [Abstract] |
Schedule of Changes in Contract Assets and Contract Liabilities | The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2024:
Dollars in thousands | Total
Contract Asset |
Contract asset, January 1, 2024 | $ | 9,233 |
Transferred to trade receivable from contract asset included in beginning of the year contract asset | (9,233) |
Contract asset, net of transferred to trade receivables on contracts during the period | 6,146 |
Contract asset, December 31, 2024 | $ | 6,146 |
Contract Liability |
Contract liability, January 1, 2024 | $ | 16,252 |
Recognition of revenue included in beginning of year contract liability | (10,307) |
Contract liability, acquired with Acclarent | 3,984 |
Contract liability, net of revenue recognized on contracts during the period | 9,874 |
Foreign currency translation | (134) |
Contract liability, December 31, 2024 | $ | 19,669 |
Schedule of Disaggregation of Revenue | The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2024, 2023, and 2022 (dollar amounts in thousands):
|  |  |  | Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022
Neurosurgery |  |  |  | $ | 803,816 |  | $ | 818,101 |  | $ | 794,017 |
Instruments |  |  |  | 204,177 |  | 203,617 |  | 192,679 |
ENT(1)(2) |  |  |  | 135,643 |  | 37,275 |  | 32,868 |
Total Codman Specialty Surgical |  |  |  | 1,143,636 |  | 1,058,993 |  | 1,019,564 |
Wound Reconstruction and Care(3)(4) |  |  |  | 350,565 |  | 373,986 |  | 406,689 |
Private Label |  |  |  | 116,326 |  | 108,594 |  | 131,413 |
Total Tissue Technologies |  |  |  | 466,891 |  | 482,580 |  | 538,102 |
Total revenue |  |  |  | $ | 1,610,527 |  | $ | 1,541,573 |  | $ | 1,557,666 |
(1) See Note 4. Acquisitions and Divestitures for details surrounding the acquisition of Acclarent on April 1, 2024. (2) Prior period revenues included within our instruments business have been reclassified under the ENT business. (3) See Note 4. Acquisitions and Divestitures for details surrounding the SIA acquisition on December 7, 2022. (4) See Note 4. Acquisitions and Divestitures for details surrounding the sale of the Company’s non-core traditional wound care (“TWC”) business on August 31, 2022.

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration